The Zombie Pattern: When Fresh Capital Buys Standing Instead of Capacity

On September 1, GoPro announced it was being acquired. Starman Optical, a privately held maker of optical transceivers, will take roughly 90% of the company in a $285 million deal. Existing shareholders receive $1.14 per share in cash and retain about 10% of the combined business, which stays listed on Nasdaq; closing is expected by the end of 2026, subject to regulatory and shareholder approval. GoPro's roughly $92 million of outstanding debt is repaid in full at closing.

The context matters more than the headline. In an August filing, GoPro told regulators that years of operating losses and deteriorating finances had raised "substantial doubt" about whether it would have enough cash to pay its bills and debts over the next year. Second-quarter revenue came in at $105 million, down 31% from a year earlier, alongside a $51 million net loss. Quarterly revenue had peaked above $630 million in the final quarter of 2014, shortly after the company went public. Back in April, GoPro had hired Oliver Wyman to identify potential defense, government and aerospace uses for its imaging technology — a notable line item, because it means the company was paying to find out what to reinvest in before it could reinvest at all.

What reinvestment intensity actually measures

The Reinvestment Intensity Index in the RaymondsIndex framework has three components: reinvestment ratio, CAPEX variability, and the investment gap. Most readers reach for the first. The investment gap is the one that earns its keep in situations like this.

A gap opens when capital arrives at a company and lands somewhere other than productive capacity. Debt gets retired. A listing requirement gets satisfied. A control block changes hands. All of these are real uses of cash, all of them appear as capital events, and none of them expands what the business can produce next year. The distinguishing property is self-financing: capacity generates the cash flow that pays for the next round of capacity, whereas standing does not generate the cash flow that buys standing again. So the same bill returns on the next cycle, at roughly the same size, and has to be met from outside again.

That is why the zombie pattern rarely looks like a company that has stopped spending. It looks like a company that keeps spending in a direction that never compounds.

Korea parallel

Korean disclosure makes the direction unusually legible, because issuers must state the purpose of a placement. On September 2, Newspim reported three KOSDAQ companies in delisting-related proceedings, all raising capital in the same fortnight, all for the same declared reason — improving financial structure and governance, which is to say preserving listing eligibility.

The outcomes diverged. Icure completed payment on August 28 for 24,177,949 new shares, an actual issue amount of ₩24,999,999,266, with control passing to Soluem Cosmetic and two others at a 39.16% stake; the exchange had granted an eight-month improvement period and the company filed its compliance report on August 4. Bucket Studio withdrew a ₩20 billion placement on August 26 — two days after the KOSDAQ Market Committee granted it a four-month improvement period running to December 24 — while separately pursuing a sale of 45,348,357 shares, a 32.75% controlling stake, under a July 28 MOU with NMSI. Terra Science moved the payment date on its ₩2.5 billion placement to September 30, its latest deferral since the deal was first resolved in November 2024.

Three announcements, one inflow. And the regulatory backdrop is tightening: a Korea Capital Market Institute researcher cited an exchange estimate that reform measures could push the number of KOSDAQ delisting candidates in 2026 to around 150, against the 50 originally expected.

Academic frame

Caballero, Hoshi and Kashyap (2008) documented how credit extended to keep impaired Japanese firms alive depressed restructuring across entire sectors — the resources were real, the renewal was real, the capacity never arrived. Myers (1977) supplies the mechanism from the other side: under debt overhang, the gains from new investment accrue first to existing claimholders, so a distressed firm rationally declines projects that would create value. Neither result requires anyone to behave badly. Both predict spending that renews rather than compounds.

What this means for an individual investor

A capital raise, a strategic merger and a rescue all produce the same headline. The separation is in the stated use of proceeds, and it is available to anyone willing to read past the amount to the destination. Ask what the money buys. If the answer is a year, ask who is expected to pay for the next one.

#RaymondsRisk #RelationalRisk #CorporateGovernance #ReinvestmentRisk #DistressedMA #KOSDAQ